EMPOWER program

Health

adminNovember 19, 2020
6

Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

Ingelheim, Germany & Indianapolis, United States: – In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total…
Read More »